Skip to content

Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain

Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03396588
Acronym
No-POPPY
Enrollment
120
Registered
2018-01-11
Start date
2017-12-07
Completion date
2024-04-10
Last updated
2025-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Abstinence Syndrome

Keywords

Opiate use during pregnancy, Clonidine, Morphine, Prenatal opiate, Neonatal Abstinence Syndrome, Infant, Newborn, Diseases, Substance-Related Disorders, Chemically-Induced Disorders, Opiate Alkaloids, Mental Disorders, Narcotics, Central Nervous System Depressants, Physiological Effects of Drugs, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Molecular Mechanisms of Pharmacological Action, Antihypertensive Agents, Analgesics, Peripheral Nervous System Agents, Sympatholytics, Autonomic Agents, Neurotransmitter Agents

Brief summary

The long term goals of our research are to establish the best pharmacological treatment for NAS and determine how pharmacologic treatment of NAS affects long-term developmental outcomes. The objective of this application is to evaluate the effectiveness of clonidine as a treatment for neonates with NAS, in a randomized clinical trial. Our central hypothesis is that clonidine will effectively treat drug withdrawal manifestations in neonates.

Detailed description

In this current proposal, the research plan is based on our pilot study, which randomized infants with NAS to receive morphine or clonidine. The treatment groups were similar as to mean birth weight, gestational age, Apgar scores, and postnatal age at treatment. Infants enrolled had no other medical or surgical complications. Treatment was initiated per our NICU standard at the time, and will be continued in this protocol. Total LOS was shorter by about 1 week in the clonidine (mean of 15 days), compared to 21 days in the morphine group. Aims and Objectives: To determine whether the treatment of NAS with a non-opiate medication, clonidine, will be more effective than morphine * Compare Clonidine and morphine for the treatment of NAS. Compare the efficacy of each drug which is determined by duration of treatment in number of days, number of dose escalations needed to achieve needed treatment, and the need for second drug treatment. * Evaluate the neurobehavioral performance scores (habituation, orientation, self- regulation, motor/reflexes, and stress/ abstinence scales) using the neonatal intensive care (NICU) network neurobehavioral scale (NNNS) in both treatment groups. This exam will take place after treatment begins, and at one month post-natal age (38-44 weeks post menstrual age) or at discharge, whichever comes first. To determine whether treatment of NAS with clonidine will result in better early childhood outcomes than those treated with morphine • Compare the cognitive, motor and behavioral development of children in both treatment groups using the Bayley III Scales of Infant Development at 6 months, one and two years of age. To build population pharmacokinetic/pharmacodynamic models and determine factors that affect exposure and response to morphine and clonidine • Measure blood levels obtained at random times and correlate to Finnegan scores. The pharmacodynamics may help with understanding NAS medications and coping measures in babies.

Interventions

DRUGClonidine

1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.

DRUGMorphine

Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Henrietta Bada
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

The study will mask parents and child caregivers, and NICU nurses giving the drug, other personnel, residents and attending physicians, and research staff. Since initial dose is set using weight based-dosing, a physician's order can be entered in the electronic medical record to give the initial study drug with the infant's weight stated in the order. Increase in dosing will be ordered as to increase by 25% of initial dose or decrease of dose by 10% of maximum dose. During the pilot study, masking of treating personnel was maintained while the hospital pharmacist was the only person aware of which study drug the infant was receiving. The examiners for administration of the NNNS and the research nurse and research case worker will be masked to treatment received. Those seeing the infant in the clinic will also be masked to the treatment assignment. Morphine and clonidine are dispensed in identical appearance, color, smell, and volume.

Intervention model description

The study is intended to treat NAS using a randomized and double-blind study design to compare the use of opiate (morphine) or non-opiate (clonidine). Newborns meeting the study criteria for drug withdrawal and treatment will be randomized to receive one of the drugs (morphine, clonidine). Newborns requiring a second drug to help relieve the symptoms will be treated with phenobarbital for both groups. Randomization, blinding and dispensing will occur in the Investigational Drug Services Unit. Nursing personnel in the NICU will be masked to the treatment administered to each baby.

Eligibility

Sex/Gender
ALL
Age
12 Hours to 7 Days
Healthy volunteers
No

Inclusion criteria

* Gestational age (GA) \> or equal to 35 weeks * Known prenatal opiate exposure (by mother admitting use, mom with positive opiate screen during pregnancy, or positive neonatal urine and meconium screening) * No known prenatal cocaine exposure * No morphine or clonidine dose before enrollment * Symptomatic with Finnegan scores (FS): 3 consecutive scores greater than or equal to 8, OR 2 consecutive scores greater than or equal to 12, and/or with attending decision to treat for NAS * Less than or equal to 7 days of age * Attending physician decides to start pharmacologic treatment and agrees to infant's study participation

Exclusion criteria

* Seizures * Major congenital malformations * Blood pressure instability * Major medical condition in addition to NAS * Parents unable to understand English

Design outcomes

Primary

MeasureTime frameDescription
Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Baseline (5-10 days post natal age) and one-month post-natal age (between 4-6 weeks of age), or at discharge, whichever comes first.The summary scores from the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) give a measure of infant neurobehavior in the following areas (score range): habituation (1-9), regulation (2.20-7.50), attention (1.29-8.4), Handling (0-1), quality of movement (1.20-6.20), Non-optimal reflexes (0-12), Asymmetric reflexes (0-7), arousal (2.43-6.67), hypertonicity (0-8), hypotonicity (0-5.0), excitability (0-11), lethargy (0-11.0), and stress/abstinence (0-0.57). A higher score for each item means a higher level of the construct. For example, a higher score for hypertonicity means the infant is more hypertonic and higher score on hypotonicity means the infant is more hypotonic. No cut-off score published for normal or abnormal behavioral performance.
Bayley Scales of Infant and Toddler Development Third Edition6 months of lifeScores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive, and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15 with a range of 55-155 for cognitive and a range of 45-155 for language and motor (lower scores indicating greater impairment). Scores below 1 standard deviation (=or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain. The score for each domain (motor, cognitive, and language functioning) represents the composite score.
Ages and Stages Questionnaire Third Edition (ASQ-3)12 months of ageThe ASQ-3 is a developmental screening tool to assess developmental progress in children. Children are scored in the areas of communication, gross motor skills, fine motor skills, problem solving, and personal/social skills. The child's parent/guardian answers whether their child already does an activity (yes=10), sometimes does it (sometimes=5), or does not yet do it (not yet=0). The answers are then used to score each category. Each category is then broken down into whether the child falls above the cutoff (child development is on schedule), close to the cutoff (child development is slightly delayed and requires monitoring/intervention), or below the cutoff (delayed development and further assessment required).
Childhood Behavior Checklist (CBCL) T-ScoresOnce post discharge (between 18 months up to 24 months of age)The CBCL/1.5-5 is validated for children ages 1.5 to 5 years old. It obtains caregivers' ratings of 113 behavior items. Scores are broken down into internalizing problems (scores range 29-100, normal is below 60), externalizing problems (scores range from 28-100, normal is below 60), and total problems (range is 28-100, normal is below 60). Items are scored on the following syndrome scales: Emotionally Reactive, Anxious/Depressed, Somatic Complaints, Withdrawn, Attention Problems, Aggressive Behavior, and Sleep Problems. Items are also scored on the following DSM-oriented scales: Affective Problems, Anxiety Problems, Pervasive Developmental Problems, Attention Deficit/Hyperactivity Problems, Stress Problems, Autism Spectrum Problems, and Oppositional Defiant Problems. The CBCL consists of 113 items, scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often)

Secondary

MeasureTime frameDescription
Duration of Treatment60 daysTotal number days of treatment
Childhood Behavior Checklist 1.5-5 T-ScoresOnce post discharge (between 18 months up to 24 months of age)On the CBCL 1.5-5, T-scores, with a mean of 50 and a standard deviation of 10, are used to interpret results, with scores of 65 or higher indicating a clinical range, and scores between 60 and 64 suggesting a borderline clinical range.

Countries

United States

Participant flow

Participants by arm

ArmCount
Clonidine
Babies randomized to clonidine will receive 1mcg/kg/dose (with a dosing interval of 3 or 4 hours). Clonidine: 1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
60
Morphine
Babies randomized to morphine will receive 0.06 mg/kg/dose (with a dosing interval of 3 or 4 hours). Morphine: Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
60
Total120

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyPhysician Decision23

Baseline characteristics

CharacteristicClonidineMorphineTotal
Age, Categorical
<=18 years
60 Participants60 Participants120 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Age, Continuous38.7 weeks
STANDARD_DEVIATION 1.2
38.3 weeks
STANDARD_DEVIATION 1.3
38.4 weeks
STANDARD_DEVIATION 1.2
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants4 Participants4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
60 Participants56 Participants116 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants0 Participants1 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
6 Participants8 Participants14 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
53 Participants52 Participants105 Participants
Region of Enrollment
United States
60 participants60 participants120 participants
Sex: Female, Male
Female
23 Participants30 Participants53 Participants
Sex: Female, Male
Male
37 Participants30 Participants67 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 600 / 60
other
Total, other adverse events
52 / 6024 / 60
serious
Total, serious adverse events
9 / 6015 / 60

Outcome results

Primary

Ages and Stages Questionnaire Third Edition (ASQ-3)

The ASQ-3 is a developmental screening tool to assess developmental progress in children. Children are scored in the areas of communication, gross motor skills, fine motor skills, problem solving, and personal/social skills. The child's parent/guardian answers whether their child already does an activity (yes=10), sometimes does it (sometimes=5), or does not yet do it (not yet=0). The answers are then used to score each category. Each category is then broken down into whether the child falls above the cutoff (child development is on schedule), close to the cutoff (child development is slightly delayed and requires monitoring/intervention), or below the cutoff (delayed development and further assessment required).

Time frame: 24 months

Population: The ASQ-3 at 24 months was used for babies who were unable to have the Bayley assessment due to COVID-19 research restrictions.~The babies who had the Bayley did not have the ASQ performed.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Gross motorClose to cutoffs1 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Fine motorBelow cutoffs2 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)CommunicationClose to cutoffs2 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Problem solvingAbove cutoffs12 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Gross motorBelow cutoffs0 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Problem solvingClose to cutoffs2 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Gross motorAbove cutoffs13 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Problem solvingBelow cutoffs0 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Fine motorAbove cutoffs8 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Personal/socialAbove cutoffs12 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)CommunicationBelow cutoffs4 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Personal/socialClose to cutoffs1 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Fine motorClose to cutoffs4 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Personal/socialBelow cutoffs1 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)CommunicationAbove cutoffs8 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Personal/socialBelow cutoffs0 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)CommunicationAbove cutoffs8 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)CommunicationClose to cutoffs2 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)CommunicationBelow cutoffs1 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Gross motorAbove cutoffs10 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Gross motorClose to cutoffs1 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Gross motorBelow cutoffs0 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Fine motorAbove cutoffs8 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Fine motorClose to cutoffs3 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Fine motorBelow cutoffs0 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Problem solvingAbove cutoffs9 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Problem solvingClose to cutoffs2 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Problem solvingBelow cutoffs0 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Personal/socialAbove cutoffs10 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Personal/socialClose to cutoffs1 Participants
Primary

Ages and Stages Questionnaire Third Edition (ASQ-3)

The ASQ-3 is a developmental screening tool to assess developmental progress in children. Children are scored in the areas of communication, gross motor skills, fine motor skills, problem solving, and personal/social skills. The child's parent/guardian answers whether their child already does an activity (yes=10), sometimes does it (sometimes=5), or does not yet do it (not yet=0). The answers are then used to score each category. Each category is then broken down into whether the child falls above the cutoff (child development is on schedule), close to the cutoff (child development is slightly delayed and requires monitoring/intervention), or below the cutoff (delayed development and further assessment required).

Time frame: 12 months of age

Population: ASQ-3 assessments were used for babies who were unable to have Bayley assessment performed due to COVID-19 research restrictions. The babies who had the Bayley did not have the ASQ.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)CommunicationAbove cutoffs6 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Fine motorBelow cutoffs0 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Gross motorClose to cutoffs0 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Problem solvingAbove cutoffs4 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)CommunicationBelow cutoffs1 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Problem solvingClose to cutoffs3 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Gross motorBelow cutoffs0 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Problem solvingBelow cutoffs0 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)CommunicationClose to cutoffs0 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Personal/socialAbove cutoffs7 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Gross motorAbove cutoffs7 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Personal/socialClose to cutoffs0 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Fine motorClose to cutoffs1 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Personal/socialBelow cutoffs0 Participants
ClonidineAges and Stages Questionnaire Third Edition (ASQ-3)Fine motorAbove cutoffs6 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Personal/socialBelow cutoffs0 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)CommunicationAbove cutoffs7 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)CommunicationClose to cutoffs3 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)CommunicationBelow cutoffs0 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Gross motorAbove cutoffs10 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Gross motorClose to cutoffs0 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Gross motorBelow cutoffs0 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Fine motorAbove cutoffs8 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Fine motorClose to cutoffs2 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Fine motorBelow cutoffs0 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Problem solvingAbove cutoffs9 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Problem solvingClose to cutoffs1 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Problem solvingBelow cutoffs0 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Personal/socialAbove cutoffs10 Participants
MorphineAges and Stages Questionnaire Third Edition (ASQ-3)Personal/socialClose to cutoffs0 Participants
Primary

Bayley Scales of Infant and Toddler Development Third Edition

Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive, and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15 with a range of 55-155 for cognitive and a range of 45-155 for language and motor (lower scores indicating greater impairment). Scores below 1 standard deviation (=or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain. The score for each domain (motor, cognitive, and language functioning) represents the composite score.

Time frame: 6 months of life

Population: Participants may not have had the 6 month Bayley due to the participant being lost to follow up, or because of COVID-19 research restrictions.

ArmMeasureGroupValue (MEAN)Dispersion
ClonidineBayley Scales of Infant and Toddler Development Third EditionCognitive113.0 score on a scaleStandard Deviation 12.8
ClonidineBayley Scales of Infant and Toddler Development Third EditionLanguage91.8 score on a scaleStandard Deviation 13.4
ClonidineBayley Scales of Infant and Toddler Development Third EditionMotor102.4 score on a scaleStandard Deviation 16.4
MorphineBayley Scales of Infant and Toddler Development Third EditionCognitive111.8 score on a scaleStandard Deviation 11.1
MorphineBayley Scales of Infant and Toddler Development Third EditionLanguage87.7 score on a scaleStandard Deviation 13.5
MorphineBayley Scales of Infant and Toddler Development Third EditionMotor97.4 score on a scaleStandard Deviation 12.3
Primary

Bayley Scales of Infant and Toddler Development Third Edition

Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive, and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15 with a range of 55-155 for cognitive and a range of 45-155 for language and motor (lower scores indicating greater impairment). Scores below 1 standard deviation (=or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain. The score for each domain (motor, cognitive, and language functioning) represents the composite score.

Time frame: 1 year of life

Population: Participants may not have had the 12 month Bayley due to the participant being lost to follow up, or because of COVID-19 research restrictions.

ArmMeasureGroupValue (MEAN)Dispersion
ClonidineBayley Scales of Infant and Toddler Development Third EditionCognitive98.2 score on a scaleStandard Deviation 11.5
ClonidineBayley Scales of Infant and Toddler Development Third EditionLanguage91.8 score on a scaleStandard Deviation 11.6
ClonidineBayley Scales of Infant and Toddler Development Third EditionMotor99.1 score on a scaleStandard Deviation 12.2
MorphineBayley Scales of Infant and Toddler Development Third EditionCognitive97.2 score on a scaleStandard Deviation 10.8
MorphineBayley Scales of Infant and Toddler Development Third EditionLanguage92.2 score on a scaleStandard Deviation 12.2
MorphineBayley Scales of Infant and Toddler Development Third EditionMotor96.2 score on a scaleStandard Deviation 9.3
Primary

Bayley Scales of Infant and Toddler Development Third Edition

Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive, and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15 with a range of 55-155 for cognitive and a range of 45-155 for language and motor (lower scores indicating greater impairment). Scores below 1 standard deviation (=or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain. The score for each domain (motor, cognitive, and language functioning) represents the composite score.

Time frame: 2 years of life

Population: Participants may not have had the 24 month Bayley due to the participant being lost to follow up, or because of COVID-19 research restrictions.

ArmMeasureGroupValue (MEAN)Dispersion
ClonidineBayley Scales of Infant and Toddler Development Third EditionCognitive84.3 score on a scaleStandard Deviation 6.7
ClonidineBayley Scales of Infant and Toddler Development Third EditionLanguage95.4 score on a scaleStandard Deviation 9.4
ClonidineBayley Scales of Infant and Toddler Development Third EditionMotor97.6 score on a scaleStandard Deviation 7.2
MorphineBayley Scales of Infant and Toddler Development Third EditionCognitive81.1 score on a scaleStandard Deviation 9.6
MorphineBayley Scales of Infant and Toddler Development Third EditionLanguage86.2 score on a scaleStandard Deviation 11
MorphineBayley Scales of Infant and Toddler Development Third EditionMotor96.0 score on a scaleStandard Deviation 9.8
Primary

Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)

The summary scores from the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) give a measure of infant neurobehavior in the following areas (score range): habituation (1-9), regulation (2.20-7.50), attention (1.29-8.4), Handling (0-1), quality of movement (1.20-6.20), Non-optimal reflexes (0-12), Asymmetric reflexes (0-7), arousal (2.43-6.67), hypertonicity (0-8), hypotonicity (0-5.0), excitability (0-11), lethargy (0-11.0), and stress/abstinence (0-0.57). A higher score for each item means a higher level of the construct. For example, a higher score for hypertonicity means the infant is more hypertonic and higher score on hypotonicity means the infant is more hypotonic. No cut-off score published for normal or abnormal behavioral performance.

Time frame: Baseline (5-10 days post natal age) and one-month post-natal age (between 4-6 weeks of age), or at discharge, whichever comes first.

Population: Some babies were unable to be assessed in certain domains and therefore were not included in the total analyzed for that domain.

ArmMeasureGroupValue (MEAN)
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Handling-0.1 score on a scale
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Arousal-0.1 score on a scale
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Regulation0.5 score on a scale
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Hypertonia-1.0 score on a scale
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Attention1.0 score on a scale
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Hypotonia0.0 score on a scale
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Non-optimal reflexes-1.0 score on a scale
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Excitability-1.0 score on a scale
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Quality of movement0.1 score on a scale
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Lethargy0.0 score on a scale
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Asymmetry total/reflexes0.0 score on a scale
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Stress abstinence0.0 score on a scale
ClonidineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Habituation0.5 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Stress abstinence0.0 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Habituation0.3 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Attention0.6 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Handling0.1 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Quality of movement0.0 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Regulation-0.2 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Non-optimal reflexes-1.0 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Asymmetry total/reflexes0.0 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Arousal0.4 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Hypertonia0.0 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Hypotonia0.0 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Excitability1.0 score on a scale
MorphineChange in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)Lethargy0.0 score on a scale
Primary

Childhood Behavior Checklist (CBCL) T-Scores

The CBCL/1.5-5 is validated for children ages 1.5 to 5 years old. It obtains caregivers' ratings of 113 behavior items. Scores are broken down into internalizing problems (scores range 29-100, normal is below 60), externalizing problems (scores range from 28-100, normal is below 60), and total problems (range is 28-100, normal is below 60). Items are scored on the following syndrome scales: Emotionally Reactive, Anxious/Depressed, Somatic Complaints, Withdrawn, Attention Problems, Aggressive Behavior, and Sleep Problems. Items are also scored on the following DSM-oriented scales: Affective Problems, Anxiety Problems, Pervasive Developmental Problems, Attention Deficit/Hyperactivity Problems, Stress Problems, Autism Spectrum Problems, and Oppositional Defiant Problems. The CBCL consists of 113 items, scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often)

Time frame: Once post discharge (between 18 months up to 24 months of age)

Population: Only children in the treated cohorts had the CBCL.~Participants who were considered lost to follow up did not have the CBCL.

ArmMeasureGroupValue (MEAN)Dispersion
ClonidineChildhood Behavior Checklist (CBCL) T-ScoresInternalizing Problems52.31 score on a scaleStandard Deviation 10.4
ClonidineChildhood Behavior Checklist (CBCL) T-ScoresExternalizing Problems54.8 score on a scaleStandard Deviation 13.4
ClonidineChildhood Behavior Checklist (CBCL) T-ScoresTotal Problems53.6 score on a scaleStandard Deviation 12.6
MorphineChildhood Behavior Checklist (CBCL) T-ScoresInternalizing Problems50.9 score on a scaleStandard Deviation 13.9
MorphineChildhood Behavior Checklist (CBCL) T-ScoresExternalizing Problems53.5 score on a scaleStandard Deviation 17
MorphineChildhood Behavior Checklist (CBCL) T-ScoresTotal Problems53.5 score on a scaleStandard Deviation 13.5
Secondary

Childhood Behavior Checklist 1.5-5 T-Scores

On the CBCL 1.5-5, T-scores, with a mean of 50 and a standard deviation of 10, are used to interpret results, with scores of 65 or higher indicating a clinical range, and scores between 60 and 64 suggesting a borderline clinical range.

Time frame: Once post discharge (between 18 months up to 24 months of age)

Population: Participants who were lost to follow up did not have the CBCL.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
ClonidineChildhood Behavior Checklist 1.5-5 T-ScoresInternalizing Problems Borderline T-Scores5 Participants
ClonidineChildhood Behavior Checklist 1.5-5 T-ScoresInternalizing Problems Clinical Range T-Scores1 Participants
ClonidineChildhood Behavior Checklist 1.5-5 T-ScoresExternalizing Problems Borderline T-Scores2 Participants
ClonidineChildhood Behavior Checklist 1.5-5 T-ScoresExternalizing Problems Clinical Range T-Scores3 Participants
ClonidineChildhood Behavior Checklist 1.5-5 T-ScoresTotal Problems Borderline T-Scores3 Participants
ClonidineChildhood Behavior Checklist 1.5-5 T-ScoresTotal Problems Clinical Range T-Scores1 Participants
MorphineChildhood Behavior Checklist 1.5-5 T-ScoresTotal Problems Borderline T-Scores2 Participants
MorphineChildhood Behavior Checklist 1.5-5 T-ScoresInternalizing Problems Borderline T-Scores2 Participants
MorphineChildhood Behavior Checklist 1.5-5 T-ScoresExternalizing Problems Clinical Range T-Scores6 Participants
MorphineChildhood Behavior Checklist 1.5-5 T-ScoresInternalizing Problems Clinical Range T-Scores8 Participants
MorphineChildhood Behavior Checklist 1.5-5 T-ScoresTotal Problems Clinical Range T-Scores8 Participants
MorphineChildhood Behavior Checklist 1.5-5 T-ScoresExternalizing Problems Borderline T-Scores2 Participants
Secondary

Duration of Treatment

Total number days of treatment

Time frame: 60 days

ArmMeasureValue (MEAN)
ClonidineDuration of Treatment17 days
MorphineDuration of Treatment15 days

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026